Cutera (CUTR) Lowered to Sell at Zacks Investment Research

Zacks Investment Research downgraded shares of Cutera (NASDAQ:CUTR) from a hold rating to a sell rating in a report issued on Tuesday morning.

According to Zacks, “Cutera Inc designs, develops, manufactures and markets the CoolGlide family of products for use in laser and other light-based aesthetic applications. The original CoolGlide CV provides permanent hair reduction on all skin types. The second generation CoolGlide Excel incorporated features that added the capability to treat a variety of vascular lesions, which include facial telangiectasia, spider and reticular leg veins. The CoolGlide Vantage added non-ablative skin therapy to the range of applications offered by the system. “

CUTR has been the topic of a number of other reports. BidaskClub upgraded Cutera from a hold rating to a buy rating in a research report on Tuesday, December 12th. Maxim Group cut Cutera from a buy rating to a hold rating in a research report on Thursday, September 14th. Finally, Roth Capital upped their price target on Cutera from $41.00 to $47.00 and gave the company a buy rating in a research report on Tuesday, September 12th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of Buy and an average target price of $37.33.

Shares of Cutera (NASDAQ CUTR) opened at $45.85 on Tuesday. Cutera has a 1 year low of $16.65 and a 1 year high of $48.95. The firm has a market capitalization of $640.10, a price-to-earnings ratio of 58.78, a price-to-earnings-growth ratio of 2.00 and a beta of 0.53.

Cutera (NASDAQ:CUTR) last announced its quarterly earnings results on Tuesday, November 7th. The medical device company reported $0.42 earnings per share for the quarter, beating analysts’ consensus estimates of $0.08 by $0.34. Cutera had a return on equity of 18.73% and a net margin of 7.99%. The firm had revenue of $38.17 million for the quarter, compared to analysts’ expectations of $34.82 million. During the same period in the prior year, the business posted $0.12 earnings per share. The business’s revenue was up 26.1% compared to the same quarter last year. equities analysts expect that Cutera will post 0.55 EPS for the current fiscal year.

In other news, Director David B. Apfelberg sold 1,000 shares of the stock in a transaction on Wednesday, October 18th. The stock was sold at an average price of $39.90, for a total transaction of $39,900.00. Following the sale, the director now owns 10,259 shares in the company, valued at $409,334.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Timothy J. Oshea sold 4,000 shares of the stock in a transaction on Monday, October 16th. The stock was sold at an average price of $39.21, for a total value of $156,840.00. The disclosure for this sale can be found here. Insiders have sold 24,950 shares of company stock worth $1,085,720 in the last 90 days. Company insiders own 3.30% of the company’s stock.

Several hedge funds have recently made changes to their positions in CUTR. Kennedy Capital Management Inc. bought a new stake in shares of Cutera during the second quarter worth $9,426,000. Stonepine Capital Management LLC bought a new stake in shares of Cutera during the second quarter worth $4,533,000. Ameriprise Financial Inc. bought a new stake in shares of Cutera during the second quarter worth $3,175,000. EAM Investors LLC grew its holdings in shares of Cutera by 148.7% during the second quarter. EAM Investors LLC now owns 197,485 shares of the medical device company’s stock worth $5,115,000 after purchasing an additional 118,073 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its holdings in shares of Cutera by 289.1% during the second quarter. Russell Investments Group Ltd. now owns 110,529 shares of the medical device company’s stock worth $2,862,000 after purchasing an additional 82,123 shares during the last quarter. Institutional investors own 87.64% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.com-unik.info/2017/12/27/cutera-cutr-lowered-to-sell-at-zacks-investment-research.html.

Cutera Company Profile

Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.

What are top analysts saying about Cutera? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cutera and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit